Experimental liver drug INT-787 studied for severe alcohol hepatitis

NCT ID NCT05639543

Terminated Disease control Sponsor: Intercept Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called INT-787 in 67 people with severe alcohol-associated hepatitis, a serious liver condition. The trial was a phase 2a proof-of-concept study, but it was terminated early. Researchers were looking at safety, how well the drug works, and how the body processes it.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

INT-787

What this could lead to

If successful, INT-787 could offer a new treatment option for severe alcohol-associated hepatitis, potentially improving liver function and survival.

What could go wrong

This was an early-phase trial that was terminated, so results are limited. The drug may not prove effective or safe in larger studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alcoholic hepatitis hepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALCOHOL-ASSOCIATED HEPATITIS

Contacts and locations

Show contact details

Locations

Baylor College of Medicine

Houston, Texas, 77030, United States
Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
CHU Angers

Angers, 49933, France
Cambridge University NHS Foundation Trust

Cambridge, United Kingdom
Clinical Translational Research Site

Miami, Florida, 33136, United States
Columbia University Medical Center/New York Presbyterian Hospital

New York, New York, 10032, United States
Henry Ford Health System

Detroit, Michigan, 48202, United States
Hopital Beaujon

Clichy, 92118, France
Hopital Claude Huriez

Lille, 59037, France
Hopital Pitie Salpetriere

Paris, 75013, France
Hopital Rangueil

Toulouse, 31059, France
Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Imperial College Healthcare NHS Trust

London, United Kingdom
Mayo Clinic

Rochester, Minnesota, 55905, United States
Medical University of South Carolina

Charleston, South Carolina, 29425, United States
Mercy Medical Center

Baltimore, Maryland, 21202, United States
Northwell Health Center for Liver Disease and Transplantation

Manhasset, New York, 11030, United States
Royal Free Hospital

London, NW3 2QG, United Kingdom
Rush University Medical Center

Chicago, Illinois, 60612, United States
Stanford Healthcare

Palo Alto, California, 94305, United States
Tampa General Medical Group

Tampa, Florida, 33606, United States
The Liver Institute at Methodist Dallas Medical Center

Dallas, Texas, 75203, United States
UC Davis Medical Center

Sacramento, California, 95817, United States
UMass Memorial Medical Center

Worcester, Massachusetts, 01655, United States
University Hospitals Plymouth NHS Trust

Plymouth, United Kingdom
University of California, San Francisco-Fresno

Fresno, California, 93701, United States
University of Utah Hospital

Salt Lake City, Utah, 84132, United States
VCU Health Clinical Research Services Unit

Richmond, Virginia, 23298, United States
Vanderbilt Digestive Disease Center

Nashville, Tennessee, 37232, United States